Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.

Shi L, Zhu J, Yang P, Tang X, Yu W, Pan C, Shen M, Zhu D, Cheng J, Ye X

Obesity research & clinical practice1 Feb 2017Cited by 24 (Europe PMC)

PMID28161303DOI10.1016/j.orcp.2017.01.003PepBankPUB-28161303

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, intra-abdominal fat was lower with metformin/exenatide than metformin/acarbose at 3 months.
In plain wordsIn patients with obesity and type 2 diabetes, abdominal fat was lower with metformin/exenatide than metformin/acarbose.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseIntra-abdominal fat versus acarbose
Study
n = 36
Comparator
Metformin/acarbose
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Intra-abdominal fat content decreased in the GLP-1 group from baseline to 3 months (17,947±5804; 13,717±3628mm², P=0.001, respectively), but was not significantly reduced in the control group (P=0.197) and at 3 months post-treatment, it was significantly lower in the GLP-1 group than control group (P=0.043).
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
Report a problemFND-2816130302
02HumanRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes receiving metformin, intra-abdominal fat decreased after exenatide treatment.
In plain wordsIn patients with obesity and type 2 diabetes taking metformin, abdominal fat decreased after exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseIntra-abdominal fat change
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
Intra-abdominal fat content
17,947 mm<sup>2</sup>
GLP-1 group, baseline
Intra-abdominal fat content
13,717 mm<sup>2</sup>
GLP-1 group, 3 months
Source sentences
Summary
Intra-abdominal fat content decreased in the GLP-1 group from baseline to 3 months (17,947±5804; 13,717±3628mm², P=0.001, respectively), but was not significantly reduced in the control group (P=0.197) and at 3 months post-treatment, it was significantly lower in the GLP-1 group than control group (P=0.043).
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
Report a problemFND-2816130301
03HumanRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, HbA1c did not differ significantly between metformin/exenatide and metformin/acarbose.
In plain wordsIn patients with obesity and type 2 diabetes, HbA1c did not differ significantly between metformin/exenatide and metformin/acarbose.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHbA1c versus acarbose
Study
n = 36
Comparator
Metformin/acarbose
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
HbA1c
7.09%
GLP-1 group, 3 months
HbA1c
7.42%
control group, 3 months
Source sentences
Summary
Glucose control, measured by HbA1c (GLP-1: 9.72±1.38; 7.09±0.60%, P<0.001, 9.46±1.25; 7.42±0.84%, P<0.001, respectively)
2 context sentences(design, population, supporting numbers)
Summary · context
significantly improved in both groups with no significant difference between them.
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
Report a problemFND-2816130304
04HumanRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, TNF-α decreased from baseline with metformin/exenatide.
In plain wordsIn patients with obesity and type 2 diabetes, TNF-α decreased from baseline with metformin/exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTNF-α change
Study
n: not reported in source
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
TNF-α, IL-6, and leptin were lower and adiponectin levels higher in the GLP-1 group at 3 months compared with baseline (all P<0.05), but not significantly changed in the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
Report a problemFND-2816130307
05HumanRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, IL-6 decreased from baseline with metformin/exenatide.
In plain wordsIn patients with obesity and type 2 diabetes, IL-6 decreased from baseline with metformin/exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseIL-6 change
Study
n: not reported in source
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
TNF-α, IL-6, and leptin were lower and adiponectin levels higher in the GLP-1 group at 3 months compared with baseline (all P<0.05), but not significantly changed in the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
Report a problemFND-2816130308
06HumanRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, LN(HOMA-IR) did not differ significantly between metformin/exenatide and metformin/acarbose.
In plain wordsIn patients with obesity and type 2 diabetes, insulin resistance did not differ significantly between metformin/exenatide and metformin/acarbose.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeInsulin resistance versus acarbose
Study
n = 36
Comparator
Metformin/acarbose
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
LN(HOMA-IR)
1.01 index (log scale)
GLP-1 group, 3 months
LN(HOMA-IR)
1.1 index (log scale)
control group, 3 months
Source sentences
Summary
and insulin resistance index LN(HOMA-IR) (GLP-1: 1.58±0.40; 1.01±0.33, P<0.001, Control: 1.53±0.57; 1.10±0.33, P=0.003, respectively) significantly improved in both groups with no significant difference between them.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
Report a problemFND-2816130306
07HumanRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, TNF-α was similar between metformin/exenatide and metformin/acarbose.
In plain wordsIn patients with obesity and type 2 diabetes, TNF-α was similar with metformin/exenatide and metformin/acarbose.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTNF-α versus acarbose
Study
n = 36
Comparator
Metformin/acarbose
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
TNF-α, IL-6 and leptin levels were similar between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
Report a problemFND-2816130311
08HumanRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, IL-6 was similar between metformin/exenatide and metformin/acarbose.
In plain wordsIn patients with obesity and type 2 diabetes, IL-6 was similar with metformin/exenatide and metformin/acarbose.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeIL-6 versus acarbose
Study
n = 36
Comparator
Metformin/acarbose
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
TNF-α, IL-6 and leptin levels were similar between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
Report a problemFND-2816130312
09HumanRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, leptin was similar between metformin/exenatide and metformin/acarbose.
In plain wordsIn patients with obesity and type 2 diabetes, leptin was similar with metformin/exenatide and metformin/acarbose.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeLeptin versus acarbose
Study
n = 36
Comparator
Metformin/acarbose
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
TNF-α, IL-6 and leptin levels were similar between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
Report a problemFND-2816130313
10HumanRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, adiponectin was higher with metformin/exenatide than metformin/acarbose at 3 months.
In plain wordsIn patients with obesity and type 2 diabetes, adiponectin was higher with metformin/exenatide than metformin/acarbose.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAdiponectin versus acarbose
Study
n = 36
Comparator
Metformin/acarbose
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Adiponectin level was higher in the GLP-1 group than the control group at 3 months (P=0.025).
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
Report a problemFND-2816130314
11HumanRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, leptin decreased from baseline with metformin/exenatide.
In plain wordsIn patients with obesity and type 2 diabetes, leptin decreased from baseline with metformin/exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseLeptin change
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
TNF-α, IL-6, and leptin were lower and adiponectin levels higher in the GLP-1 group at 3 months compared with baseline (all P<0.05), but not significantly changed in the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
Report a problemFND-2816130309
12HumanRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, adiponectin increased from baseline with metformin/exenatide.
In plain wordsIn patients with obesity and type 2 diabetes, adiponectin increased from baseline with metformin/exenatide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAdiponectin change
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
TNF-α, IL-6, and leptin were lower and adiponectin levels higher in the GLP-1 group at 3 months compared with baseline (all P<0.05), but not significantly changed in the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
Report a problemFND-2816130310

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

13HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, HbA1c improved in both metformin/exenatide and metformin/acarbose groups.
In plain wordsIn patients with obesity and type 2 diabetes, HbA1c improved in both treatment groups, including metformin/exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c change in both groups
Study
n = 36
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c
9.72%
GLP-1 group, baseline
HbA1c
7.09%
GLP-1 group, 3 months
HbA1c
9.46%
control group, baseline
HbA1c
7.42%
control group, 3 months
Source sentences
Summary
Glucose control, measured by HbA1c (GLP-1: 9.72±1.38; 7.09±0.60%, P<0.001, 9.46±1.25; 7.42±0.84%, P<0.001, respectively)
2 context sentences(design, population, supporting numbers)
Summary · context
significantly improved in both groups with no significant difference between them.
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2816130303
14HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with obesity and type 2 diabetes, LN(HOMA-IR) improved in both metformin/exenatide and metformin/acarbose groups.
In plain wordsIn patients with obesity and type 2 diabetes, insulin resistance improved in both treatment groups, including metformin/exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInsulin resistance change in both groups
Study
n = 36
Outcome group
Glycemic control · Metabolic and weight
Measurements
LN(HOMA-IR)
1.58 index (log scale)
GLP-1 group, baseline
LN(HOMA-IR)
1.01 index (log scale)
GLP-1 group, 3 months
LN(HOMA-IR)
1.53 index (log scale)
control group, baseline
LN(HOMA-IR)
1.1 index (log scale)
control group, 3 months
Source sentences
Summary
and insulin resistance index LN(HOMA-IR) (GLP-1: 1.58±0.40; 1.01±0.33, P<0.001, Control: 1.53±0.57; 1.10±0.33, P=0.003, respectively) significantly improved in both groups with no significant difference between them.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2816130305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.

Summary

Results from this study14

Studies that did not test the peptide alone2

Version history

Subjects

Publication types

MeSH terms

Keywords